Peripheral immune factors aiding clinical parameter for better early recurrence prediction of hepatocellular carcinoma after thermal ablation

References

• Villanueva A. Hepatocellular carcinoma. N Engl J Med. 2019;380(15):1450–1462.
   PubMed Web of Science ®Google Scholar
• Portolani N, Coniglio A, Ghidoni S, et al. Early and late recurrence after liver resection for hepatocellular carcinoma: prognostic and therapeutic implications. Ann Surg. 2006;243(2):229–235.
   PubMed Web of Science ®Google Scholar
• Erridge S, Pucher PH, Markar SR, et al. Meta-analysis of determinants of survival following treatment of recurrent hepatocellular carcinoma. Br J Surg. 2017;104(11):1433–1442.
   PubMed Web of Science ®Google Scholar
• Yoo J, Lee MW, Lee DH, et al. Evaluation of a serum tumour marker-based recurrence prediction model after radiofrequency ablation for hepatocellular carcinoma. Liver Int. 2020;40(5):1189–1200.
   PubMed Web of Science ®Google Scholar
• Kobayashi T, Aikata H, Kobayashi T, et al. Patients with early recurrence of hepatocellular carcinoma have poor prognosis. Hepatobiliary Pancreat Dis Int. 2017;16(3):279–288.
   PubMed Web of Science ®Google Scholar
• Shinkawa H, Tanaka S, Kabata D, et al. The Prognostic impact of tumor differentiation on recurrence and survival after resection of hepatocellular carcinoma is dependent on tumor size. Liver Cancer. 2021;10(5):461–472.
   PubMed Web of Science ®Google Scholar
• Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology. 2011;140(5):1501–1512.e2.
   PubMed Web of Science ®Google Scholar
• Roayaie S, Blume IN, Thung SN, et al. A system of classifying microvascular invasion to predict outcome after resection in patients with hepatocellular carcinoma. Gastroenterology. 2009;137(3):850–855.
   PubMed Web of Science ®Google Scholar
• Craig AJ, von Felden J, Garcia-Lezana T, et al. Tumour evolution in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2020;17(3):139–152.
   PubMed Web of Science ®Google Scholar
• Zheng C, Zheng L, Yoo JK, et al. Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing. Cell. 2017;169(7):1342–1356.e16.
   PubMed Web of Science ®Google Scholar
• Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma. Nat Immunol. 2018;19(3):222–232.
   PubMed Web of Science ®Google Scholar
• Lim CJ, Lee YH, Pan L, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2019;68(5):916–927.
   PubMed Web of Science ®Google Scholar
• Kurebayashi Y, Ojima H, Tsujikawa H, et al. Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification. Hepatology. 2018;68(3):1025–1041.
   PubMed Web of Science ®Google Scholar
• Myers RP, Fong A, Shaheen AA. Utilization rates, complications and costs of percutaneous liver biopsy: a population-based study including 4275 biopsies. Liver Int. 2008;28(5):705–712.
   PubMed Web of Science ®Google Scholar
• Allen BM, Hiam KJ, Burnett CE, et al. Systemic dysfunction and plasticity of the immune macroenvironment in cancer models. Nat Med. 2020;26(7):1125–1134.
   PubMed Web of Science ®Google Scholar
• Hiam-Galvez KJ, Allen BM, Spitzer MH. Systemic immunity in cancer. Nat Rev Cancer. 2021;21(6):345–359.
   PubMed Web of Science ®Google Scholar
• Sprinzl MF, Kirstein MM, Koch S, et al. Improved prediction of survival by a risk factor-integrating inflammatory score in sorafenib-treated hepatocellular carcinoma. Liver Cancer. 2019;8(5):387–402.
   PubMed Web of Science ®Google Scholar
• Kuhns MS, Davis MM, Garcia KC. Deconstructing the form and function of the TCR/CD3 complex. Immunity. 2006;24(2):133–139.
   PubMed Web of Science ®Google Scholar
• Borst J, Ahrends T, Bąbała N, et al. CD4(+) T cell help in cancer immunology and immunotherapy. Nat Rev Immunol. 2018;18(10):635–647.
   PubMed Web of Science ®Google Scholar
• Zhang N, Bevan MJ. CD8(+) T cells: foot soldiers of the immune system. Immunity. 2011;35(2):161–168.
   PubMed Web of Science ®Google Scholar
• Henson SM, Riddell NE, Akbar AN. Properties of end-stage human T cells defined by CD45RA re-expression. Curr Opin Immunol. 2012;24(4):476–481.
   PubMed Web of Science ®Google Scholar
• Esensten JH, Helou YA, Chopra G, et al. CD28 costimulation: from mechanism to therapy. Immunity. 2016;44(5):973–988.
   PubMed Web of Science ®Google Scholar
• Filaci G, Fenoglio D, Fravega M, et al. CD8+ CD28- T regulatory lymphocytes inhibiting T cell proliferative and cytotoxic functions infiltrate human cancers. J Immunol. 2007;179(7):4323–4334.
   PubMed Web of Science ®Google Scholar
• Baecher-Allan C, Viglietta V, Hafler DA. Human CD4 + CD25+ regulatory T cells. Semin Immunol. 2004;16(2):89–98.
   PubMed Web of Science ®Google Scholar
• Freud AG, Mundy-Bosse BL, Yu J, et al. The broad spectrum of human natural killer cell diversity. Immunity. 2017;47(5):820–833.
   PubMed Web of Science ®Google Scholar
• Godfrey DI, Le Nours J, Andrews DM, et al. Unconventional T cell targets for cancer immunotherapy. Immunity. 2018;48(3):453–473.
   PubMed Web of Science ®Google Scholar
• Singal AG, Hoshida Y, Pinato DJ, et al. International Liver cancer association (ILCA) white paper on biomarker development for hepatocellular carcinoma. Gastroenterology. 2021;160(7):2572–2584.
   PubMed Web of Science ®Google Scholar
• Llovet JM, De Baere T, Kulik L, et al. Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(5):293–313.
   PubMed Web of Science ®Google Scholar
• Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the milan criteria. Ann Surg. 2010;252(6):903–912.
   PubMed Web of Science ®Google Scholar
• Fujita M, Yamaguchi R, Hasegawa T, et al. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020;53:102659.
   PubMed Web of Science ®Google Scholar
• Xin Y, Yang Y, Liu N, et al. Prognostic significance of systemic immune-inflammation index-based nomogram for early stage hepatocellular carcinoma after radiofrequency ablation. J Gastrointest Oncol. 2021;12(2):735–750.
   PubMed Web of Science ®Google Scholar
• Chen Y, Yang Y, Zhang XY, et al. Nomogram Based on neutrophil-to-Lymphocyte ratio and platelet-to-lymphocyte ratio to predict recurrence in patients with hepatocellular carcinoma after radiofrequency ablation. Cardiovasc Intervent Radiol. 2021;44(10):1551–1560.
   PubMed Web of Science ®Google Scholar
• Spitzer MH, Carmi Y, Reticker-Flynn NE, et al. Systemic Immunity is required for effective cancer immunotherapy. Cell. 2017;168(3):487–502.e15.]
   PubMed Web of Science ®Google Scholar
• Fu J, Xu D, Liu Z, et al. Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology. 2007;132(7):2328–2339.
   PubMed Web of Science ®Google Scholar
• Beltra JC, Manne S, Abdel-Hakeem MS, et al. Developmental Relationships of four exhausted CD8(+) T cell subsets reveals underlying transcriptional and epigenetic landscape control mechanisms. Immunity. 2020;52(5):825–841.e8.
   PubMed Web of Science ®Google Scholar
• Meyer C, Cagnon L, Costa-Nunes CM, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother. 2014;63(3):247–257.
   PubMed Web of Science ®Google Scholar
• Gebhardt C, Sevko A, Jiang H, et al. Myeloid Cells and related chronic inflammatory factors as novel predictive markers in melanoma treatment with ipilimumab. Clin Cancer Res. 2015;21(24):5453–5459.
   PubMed Web of Science ®Google Scholar
• Huff WX, Kwon JH, Henriquez M, et al. The Evolving role of CD8(+)CD28(-) immunosenescent T cells in cancer immunology. Int J Mol Sci. 2019;20(11):2810.
   PubMed Web of Science ®Google Scholar
• Casado JG, Soto R, DelaRosa O, et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother. 2005;54(12):1162–1171.
   PubMed Web of Science ®Google Scholar
• Chen C, Chen D, Zhang Y, et al. Changes of CD4 + CD25 + FOXP3+ and CD8 + CD28- regulatory T cells in non-small cell lung cancer patients undergoing surgery. Int Immunopharmacol. 2014;18(2):255–261.
   PubMed Web of Science ®Google Scholar
• Böttcher JP, Bonavita E, Chakravarty P, et al. NK Cells stimulate recruitment of cDC1 into the tumor microenvironment promoting cancer immune control. Cell. 2018;172(5):1022–1037.e14.
   PubMed Web of Science ®Google Scholar
• Durgan K, Ali M, Warner P, et al. Targeting NKT cells and PD-L1 pathway results in augmented anti-tumor responses in a melanoma model. Cancer Immunol Immunother. 2011;60(4):547–558.
   PubMed Web of Science ®Google Scholar
• Krijgsman D, de Vries NL, Skovbo A, et al. Characterization of circulating T-, NK-, and NKT cell subsets in patients with colorectal cancer: the peripheral blood immune cell profile. Cancer Immunol Immunother. 2019;68(6):1011–1024.
   PubMed Web of Science ®Google Scholar
• Zhou SL, Zhou ZJ, Hu ZQ, et al. Tumor-Associated neutrophils recruit macrophages and T-Regulatory cells to promote progression of hepatocellular carcinoma and resistance to sorafenib. Gastroenterology. 2016;150(7):1646–1658.e17.
   PubMed Web of Science ®Google Scholar
• Wang Y, Peng C, Cheng Z, et al. The prognostic significance of preoperative neutrophil-lymphocyte ratio in patients with hepatocellular carcinoma receiving hepatectomy: a systematic review and meta-analysis. Int J Surg. 2018;55:73–80.
   PubMed Web of Science ®Google Scholar
• Tefany FJ, Barnetson RS, Halliday GM, et al. Immunocytochemical analysis of the cellular infiltrate in primary regressing and non-regressing malignant melanoma. J Invest Dermatol. 1991;97(2):197–202.
   PubMed Web of Science ®Google Scholar
• Hernberg M, Muhonen T, Turunen JP, et al. The CD4+/CD8+ ratio as a prognostic factor in patients with metastatic melanoma receiving chemoimmunotherapy. J Clin Oncol. 1996;14(5):1690–1696.
   PubMed Web of Science ®Google Scholar
• Chen T, Song D, Min Z, et al. Perioperative dynamic alterations in peripheral regulatory T and B cells in patients with hepatocellular carcinoma. J Transl Med. 2012;10:14.
   PubMed Web of Science ®Google Scholar